Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection

Abstract

Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes. Therefore, we conducted this systematic review to investigate the efficacy of daclatasvir in HCV genotype 4 treatment. A computer literature search of PubMed, Scopus, Embase, Ovid, Web of knowledge, and Cochrane central was conducted. We selected studies comparing daclatasvir plus peginterferon-alfa/ribavirin versus placebo plus peginterferon-alfa/ ribavirin in patients with HCV genotype 4 infection. Pooling data from two randomized controlled trials (n = 154 patients) showed that daclatasvir/peginterferon/ribavirin treatment achieved a moderate sustained virologic response rate of 76% after 12 weeks and of 79% after 24 weeks. The daclatasvir containing regimen was superior to the placebo containing regimen in terms of virologic response rates after 12 weeks (RR=1.9% CI 1.3 to 2.6) and 24 weeks (RR=1.8% CI 1.3 to 2.5). More effective regimens are needed for HCV genotype 4. Article InfoReceived:10 October 2016 Accepted:13

Effect of sofosbuvir plus daclatasvir on virological response and liver function tests as a line of treatment for HCV related cirrhosis (a prospective cohort study)

“…The authors reported that the regimen achieved 99% SVR in patients with chronic genotype 4 infection [12]. Similarly, daclatasvir containing regimen achieved 95% SVR in patients with genotype 4 infection [13].…”

Frequency of Hepatitis C Infection in Hospital Patients in Ha'il, KSA: A Retrospective Analysis

“…Therefore, HCV infection is still significant public health and economic concern in many parts of the world. HCV infection affects more than 130 million people worldwide, with nearly half a million people dying each year from HCV-related liver diseases as it is not easy to treat so far [2][3][4][5][6]. According to the last five years' data record collected by the ministry of health of the Kingdom of Saudi Arabia (KSA), there is a notable increase in the incidence rate of hepatitis C in the kingdom (Incidence rate/100000 population: 5.48 to 10.27) [7].…”

Genomic divergence of Hepatitis C virus towards common prescribed interferon regimens on sustained virologic response (SVR) ‎

“…The phylogenetic analysis of HCV isolates from various parts of the world demonstrated six major hepatitis C virus (HCV) genotypes, known as types1-6, as well as various subtypes [12], and a newly discovered seventh type (Innogenetic). Variants isolate obtained predominantly in Southeast Asia were discovered to differ among types and subtypes [13,14]. They were integrated into their nearest phylogenetic type (all type 6, except one type 3 strain).…”